FH and hereditary leiomyomatosis and renal cell cancer: A phase II study of bevacizumab and erlotinib (epidermal growth factor receptor (EGFR) inhibitor) that enriched for patients with FH-deficient RCCs (either HLRCC or papillary RCC) reported an overall ORR of 51% (42/83 patients, CI 40–61%) and an HLRCC cohort ORR of 64% (27/42 patients, 95% CI 49–77%) [77].